查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球精準腫瘤學市場趨勢與成長機會
市場調查報告書
商品編碼
1389139

全球精準腫瘤學市場趨勢與成長機會

Global Precision Oncology Market Trends and Growth Opportunities
出版日期: | 出版商: Frost & Sullivan | 英文 78 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

官民合作關係增加了精準腫瘤學的取得和普及，增加了綜合服務和解決方案的潛力

根據患者的遺傳傾向準確識別生物標記相關的過程很複雜，並且依賴參與配對過程的腫瘤學家、決策支援科學家或其他醫療保健專業人員的專業知識和知識。精準腫瘤學旨在為腫瘤學家提供診斷、預後和治療工具，以根據患者的基因組成製定治療方案。

獲取、儲存和處理高品質的生物材料以及透過縱向資料收集有組織的臨床資訊是一項挑戰。在處理患者資料時，與醫療機構內外的分析平台同意並安全地共用敏感資料是真正的問題。人工智慧、機器學習、機器人和基於巨量資料的多組體學工具等新技術正在促進和提高標靶治療的準確性和發展。

需要進行廣泛的腫瘤分析來識別準確的遺傳生物標記和可操作的標靶。準確的診斷對於為患者提供個體化治療至關重要。確定可以預測患者治療反應和副作用發生的特定生物標記物，並確定哪些亞群將從特定治療方法中受益至關重要。這有助於考慮遺傳傾向。

精準腫瘤學改變了臨床試驗的設計，催生了基於精準診斷的測試，例如傘式測試和籃式測試。這些試驗根據促癌因素的異常而不是癌症的類型來治療患者。最新的類型是 N-of-1 試驗，通常稱為以患者為中心的試驗，它評估患者特定的治療方法組合。

精準腫瘤學涉及仔細監測，以評估腫瘤對治療的反應，並在預期出現抗藥性時改變治療方法。治療後也可以透過分子檢測來檢測抗藥性突變。使用血漿循環性腫瘤細胞cDNA 分析進行非侵入性疾病負擔監測是革命性的。

這項研究揭示了當前的技術趨勢，並強調了為確保更多癌症患者很快就受益於精準腫瘤學所做的多學科努力。它還強調了關鍵的市場促進因素和促進因素、合作夥伴關係以及影響市場成長的當前和未來的市場趨勢。產業使用案例可讓您快速了解致力於開發精準腫瘤學顛覆性技術和藥物的改變遊戲規則的參與公司。這項研究根據臨床需求、使用案例、商業模式、預防醫學、打入市場策略和技術趨勢為市場提供了新的成長機會。

目錄

戰略問題

  • 為什麼成長如此困難？
  • The Strategic Imperative 8（TM）
  • 三大戰略挑戰對全球精準腫瘤產業的影響
  • 成長機會推動Growth Pipeline Engine（TM）

成長機會分析

  • 分析範圍
  • 全球癌症負擔
  • 精準腫瘤學途徑
  • 精準腫瘤學概述 - 從患者到標靶治療的開發
  • 影響精準腫瘤學進展的因素
  • 推動精準腫瘤學採用的主要趨勢與策略
  • 精準腫瘤學商業模式 - PPP
  • 精準腫瘤學商業模式 - 公司策略
  • 生長促進因子
  • 成長抑制因素
  • 精準腫瘤供應商生態系統

精準腫瘤學研究與開發

  • 挑戰 - 研究與開發
  • 概述-標靶藥物開發流程
  • 精準腫瘤學檢測
  • 下一代精準腫瘤學測試
  • 將基因組篩檢涵蓋臨床試驗的潛在好處
  • 精準腫瘤學研究和發展的未來策略

推動精準腫瘤學研究和開發的國家舉措

  • 體學主導-舉措
  • 政府主導的搜尋精準腫瘤臨床試驗舉措- Canadian Precision Oncology Trial Finder
  • 推進精準腫瘤學測試的學術支持計劃 - MatchMiner

精準腫瘤篩檢、診斷、預後及治療選擇

  • 挑戰 - 高精準度診斷、預後預測、治療選擇
  • 概述 - 精準癌症篩檢、診斷、預後、治療選擇
  • 精準診斷、預後預測和治療選擇的未來策略

精準腫瘤監測及存活護理

  • 挑戰 - 監測和倖存者護理
  • 概述 - 影響癌症存活照護的關鍵因素
  • 癌症倖存者的長期照護管理
  • 癌症治療的未來策略

體學和資訊學在推進精準腫瘤學中不斷變化的作用

  • 挑戰-體學與資訊學
  • 體學和資訊學的優勢
  • 體學管道 - 來自多組體學平台的資訊流
  • 多組體學分析在精準腫瘤學的應用
  • 資訊學在精準腫瘤學的應用
  • 人工智慧在精準腫瘤學的應用

創新企業

  • 羅氏集團（瑞士）
  • 產業使用案例與分析師觀點
  • Caris生命科學（美國）
  • 產業使用案例與分析師觀點
  • Acrivon Therapeutics（美國）
  • Massive Bio（美國）
  • 產業使用案例與分析師觀點
  • 波士頓基因（美國）
  • 產業使用案例與分析師觀點
  • Outcomes4Me（美國）
  • 產業使用案例與分析師觀點

成長機會領域

  • 成長機會 1 - 用於治療計劃和選擇的人工智慧
  • 成長機會 2 – 擴大治療診斷的採用
  • 成長機會3 - 綜合癌症資料平台
  • 成長機會 4 - PPP 模式拓展亞太地區精準腫瘤學
  • 圖表列表
  • 免責聲明
簡介目錄
Product Code: PF69-52

Public-private Partnerships Will Propel Access and Adoption of Precision Oncology Enhancing the Potential for Integrated Services and Solutions

The procedure for accurately identifying a biomarker correlation based on a patient's genetic makeup is complex and relies on the expertise and knowledge of an oncologist, decision-support scientist, or other healthcare professional involved in the matching process. Precision oncology aims to provide oncologists with diagnosis, prognosis, and treatment tools to tailor the treatment according to patients' genetic makeup.

Acquiring, storing, and processing high-quality biomaterials and collecting organized clinical information with longitudinal data sets is a challenge. Consent and securely sharing sensitive data with analytical platforms within and outside healthcare organizations are practical problems when dealing with patient data. Emerging technologies such as AI, ML, robotics, and big data-based multi-omics tools are enabling and improving the precision and development of targeted treatments.

Extensive tumor profiling is required for the identification of accurate genetic biomarkers and actionable targets. Accurate diagnosis is crucial for implementing personalized treatment for patients. It is crucial to identify specific biomarkers that can predict both the response to treatment and the occurrence of adverse effects in patients, to determine the subpopulation that would benefit from a particular therapy. This helps to account for genetic predisposition.

Precision oncology has changed clinical trial design, resulting in precision diagnostics-based studies such as umbrella trials and basket trials. These studies treat patients based on their oncogenic driver aberration, not their cancer kind. The most recent type is N-of-1 studies, often called patient-centered trials, which assess patient-specific therapy combinations.

Precision oncology uses careful monitoring to assess tumor response to therapy and change therapeutic actions if drug resistance is anticipated. Post-treatment molecular testing may detect resistance mutations. Noninvasive disease burden monitoring using plasma circulating tumor cell cDNA analysis is a breakthrough.

This study highlights current technological trends and emphasizes the interdisciplinary efforts underway to ensure that a greater number of cancer patients can benefit from precision oncology soon. The study also highlights some of the key market drivers and restraints, partnerships, and present and future market trends that affect the growth of the market. Industry use cases will provide brief insights into some of the game-changing participants who are working toward developing disruptive technologies and drugs for precision oncology. The study will provide emerging growth opportunities for the market based on clinical need, use cases, business models, preventive care, market access strategies, and technology trends.

Table of Contents

Strategic Imperatives

  • Why is it Increasingly Difficult to Grow?
  • The Strategic Imperative 8™
  • The Impact of the Top 3 Strategic Imperatives on the Global Precision Oncology Industry
  • Growth Opportunities Fuel the Growth Pipeline Engine™

Growth Opportunity Analysis

  • Scope of Analysis
  • The Global Cancer Burden
  • Precision Oncology Pathway
  • Overview of Precision Oncology-From the Patient to the Development of Targeted Therapeutics
  • Factors Impacting the Advancement of Precision Oncology
  • Key Trends and Strategies Driving Precision Oncology's Implementation
  • Precision Oncology Business Model-PPPs
  • Precision Oncology Business Model-Strategies by Different Players
  • Growth Drivers
  • Growth Restraints
  • Precision Oncology Vendor Ecosystem

Precision Oncology R&D

  • Challenges-R&D
  • Overview-Targeted Drug Development Process
  • Precision Oncology Trials
  • Next-generation Precision Oncology Trials
  • Potential Advantages of Incorporating Genomic Screening in Clinical Trials
  • Future Strategies for Precision Oncology R&D

Country-level Initiatives to Drive Precision Oncology R&D

  • PPP-driven Initiative To Promote Precision Oncology-Omico
  • A Government-backed Initiative To Promote Precision Oncology Trials-Canadian Precision Oncology Trial Finder
  • Academic-backed Initiative To Promote Precision Oncology Trials-MatchMiner

Precision Oncology Screening, Diagnosis, Prognosis and Treatment Selection

  • Challenges-Precision Diagnostics, Prognosis, and Treatment Selection
  • Overview-Precision Cancer Screening, Diagnosis, Prognosis, and Treatment Selection
  • Future Strategies for Precision Diagnostics, Prognosis, and Treatment Selection

Precision Oncology Monitor and Survivorship Care

  • Challenges-Monitor and Survivorship Care
  • Overview-Key Factors Impacting Cancer Survivorship Care
  • Long-term Care Management for Cancer Survivors
  • Future Strategies for Cancer Care

Evolving Role of Omics and Informatics in Advancing Precision Oncology

  • Challenges-Omics and Informatics
  • Advantages of Omics and Informatics
  • The Omics Pipeline-The Information Flow from Multiomics Platforms
  • The Application of Multi-omics Analysis in Precision Oncology
  • The Application of Informatics in Precision Oncology
  • The Application of AI in Precision Oncology

Innovative Companies Propelling Precision Oncology

  • Roche Group, Switzerland
  • Industry Use Case and Analyst Perspective
  • Caris Life Sciences, United States
  • Industry Use Case and Analyst Perspective
  • Acrivon Therapeutics, United States
  • Massive Bio, United States
  • Industry Use Case and Analyst Perspective
  • BostonGene, the United States
  • Industry Use Case and Analyst Perspective
  • Outcomes4Me, United States
  • Industry Use Case and Analyst Perspective

Growth Opportunity Universe

  • Growth Opportunity 1-AI for Treatment Planning and Selection
  • Growth Opportunity 2-The Increasing Adoption of Theranostics
  • Growth Opportunity 3-Integrated Cancer Data Platforms
  • Growth Opportunity 4-The PPP Model Will Scale Precision Oncology in APAC
  • List of Exhibits
  • Legal Disclaimer